Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:707 |
Name | B-cell lymphoma |
Definition | A non-Hodgkin lymphoma that has_material_basis_in B cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Completed | USA | TUR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | BRA | BEL | ARG | 5 |
NCT01087294 | Phase I | Anti-CD19 CAR-T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT01109069 | Phase II | Ibrutinib | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01371630 | Phase Ib/II | Inotuzumab ozogamicin Cyclophosphamide + Cytarabine + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Rituximab Cytarabine + Inotuzumab ozogamicin + Methotrexate | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT01695941 | Phase I | Alisertib + Bortezomib + Rituximab | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01742988 | Phase Ib/II | Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Completed | USA | 0 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT01859819 | Phase II | Cytarabine + Rituximab | Treatment for Advanced B-Cell Lymphoma | Completed | USA | 0 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Completed | USA | 0 |
NCT02006485 | Phase I | Ublituximab + Umbralisib Ibrutinib | Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies | Completed | USA | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | POL | DEU | CZE | 0 |
NCT02153580 | Phase I | Etoposide Cyclophosphamide + Fludarabine Bendamustine | Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02199184 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT02207062 | Phase I | Ibrutinib | Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02213913 | Phase Ib/II | Lenalidomide Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT02253992 | Phase Ib/II | Nivolumab + Urelumab | Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma | Terminated | USA | FRA | ESP | DEU | 0 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02272686 | Phase II | Ibrutinib | Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma | Terminated | USA | 0 |
NCT02290951 | Phase I | Rituximab Odronextamab | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1) | Active, not recruiting | USA | ISR | GBR | FRA | DEU | 0 |
NCT02315612 | Phase I | Anti-CD22 CAR T cells | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | Completed | USA | 0 |
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02343120 | Phase I | Zanubrutinib | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | Completed | USA | NZL | ITA | GBR | AUS | 1 |
NCT02393157 | Phase II | Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) | Recruiting | USA | 0 |
NCT02395601 | Phase I | CPI-1205 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | Completed | USA | 0 |
NCT02436707 | Phase II | Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT02443077 | Phase III | Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Active, not recruiting | USA | 1 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02500407 | Phase I | Atezolizumab + Mosunetuzumab-axgb | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | GBR | ESP | DEU | CAN | AUS | 1 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02569476 | Phase I | Obinutuzumab + Zanubrutinib | BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies | Completed | USA | AUS | 1 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | GBR | ESP | 0 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02624986 | Phase Ib/II | Idasanutlin + Obinutuzumab | A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | NZL | DEU | AUS | 1 |
NCT02628405 | Phase Ib/II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Completed | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT02706405 | Phase I | Cyclophosphamide + Durvalumab + JCAR014 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02715843 | Expanded access | MT-3724 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | No longer available | USA | 0 |
NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Completed | USA | NLD | ITA | GBR | FRA | DEU | 1 |
NCT02846935 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | Completed | USA | 0 |
NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |
NCT02898259 | Phase Ib/II | Ixazomib + Lenalidomide + Rituximab | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | Terminated | USA | 0 |
NCT02914938 | Phase I | zandelisib Rituximab + zandelisib | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Terminated | USA | CHE | 0 |
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Completed | USA | GBR | FRA | 1 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02973113 | Phase I | EB-VST cells + Nivolumab | Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) | Completed | USA | 0 |
NCT02992522 | Phase I | Lenalidomide + Obinutuzumab + Venetoclax | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02997761 | Phase II | Blinatumomab + Ibrutinib | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT03028103 | Phase I | Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects | Completed | USA | 0 |
NCT03036904 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) | Completed | USA | 0 |
NCT03038672 | Phase II | Nivolumab + Varlilumab Nivolumab | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03103971 | Phase I | Cyclophosphamide + Fludarabine + HuJCAR014 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT03129828 | Phase Ib/II | Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) | Active, not recruiting | DEU | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03153462 | Expanded access | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | USA | 0 |
NCT03217253 | Phase I | Tazemetostat | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | Withdrawn | USA | 0 |
NCT03223610 | Phase I | Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Recruiting | USA | 0 |
NCT03263026 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Enzastaurin | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 | Completed | USA | 1 |
NCT03274492 | Phase III | Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX) | Active, not recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT03277729 | Phase Ib/II | CD20 CAR-T cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Completed | USA | GBR | 0 |
NCT03310619 | Phase Ib/II | Durvalumab + Lisocabtagene maraleucel | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) | Completed | USA | 0 |
NCT03328078 | Phase I | CA-4948 | A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | POL | ITA | ISR | FRA | ESP | CZE | 0 |
NCT03410901 | Phase I | BMS-986178 + SD-101 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03483103 | Phase II | Lisocabtagene maraleucel | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Completed | USA | 0 |
NCT03484702 | Phase II | Lisocabtagene maraleucel | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) | Completed | NLD | ITA | GBR | FRA | FIN | ESP | DEU | CHE | BEL | AUT | 1 |
NCT03488251 | Phase II | Gemcitabine + MT-3724 + Oxaliplatin | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT03570892 | Phase III | Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUT | AUS | 5 |
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Active, not recruiting | USA | ISR | ESP | DEU | CAN | 0 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03589469 | Phase II | Loncastuximab tesirine-lpyl | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | USA | ITA | GBR | CHE | 0 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03605589 | Phase I | Blinatumomab + Pembrolizumab | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT03620578 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152) | Active, not recruiting | NLD | BEL | 0 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03645395 | Phase II | Lenalidomide + MT-3724 | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) | Terminated | USA | 0 |
NCT03671590 | Phase I | Edralbrutinib Edralbrutinib + Ublituximab + Umbralisib | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | Terminated | POL | AUS | 0 |
NCT03684980 | Phase I | Glucarpidase + Leucovorin + Methotrexate + Rituximab | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A | Recruiting | USA | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03704298 | Phase Ib/II | axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) | Terminated | USA | 0 |
NCT03704714 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | Suspended | USA | 0 |
NCT03742258 | Phase I | Cyclophosphamide + Doxorubicin + Mivavotinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | Unknown status | USA | 0 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | USA | 0 |
NCT03749018 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03761056 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) | Completed | USA | FRA | AUS | 0 |
NCT03778073 | Phase I | Cosibelimab | Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT03793140 | Phase II | CPI-613 | A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations | Active, not recruiting | USA | 0 |
NCT03804996 | Phase I | TG-1801 + Ublituximab TG-1801 | Study of TG-1801 in Subjects With B-Cell Lymphoma | Completed | AUS | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03922204 | Phase I | MCLA-145 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | Active, not recruiting | USA | NLD | ESP | BEL | 0 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03990961 | Phase II | Pembrolizumab | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Completed | USA | 0 |
NCT03995147 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Sulfate | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Active, not recruiting | USA | 1 |
NCT04023071 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 | FT516 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
NCT04045028 | Phase I | Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Terminated | USA | 1 |
NCT04074330 | Phase Ib/II | Rituximab + Subasumstat | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04094311 | Phase III | Tisagenlecleucel | Study of Out of Specification for Tisagenlecleucel | Recruiting | CAN | 1 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04161118 | Phase II | huCART19 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) | Terminated | DEU | 0 |
NCT04161248 | Phase I | Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT04170283 | Phase III | Zanubrutinib | Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies | Enrolling by invitation | USA | TUR | SWE | POL | NZL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CZE | AUS | 2 |
NCT04205838 | Phase II | Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04210219 | Phase I | JNJ-64264681 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | POL | GBR | 4 |
NCT04214886 | Phase I | CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04220008 | Phase II | Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | Withdrawn | 0 | |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Completed | USA | CAN | 0 |
NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04245722 | Phase I | Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Terminated | USA | 0 |
NCT04257578 | Phase Ib/II | Acalabrutinib + axicabtagene ciloleucel | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | USA | 0 |
NCT04263584 | Phase II | Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) | Active, not recruiting | DEU | 0 |
NCT04285268 | Phase II | Bortezomib + Rituximab + Venetoclax | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Terminated | USA | 0 |
NCT04331119 | Phase II | Duvelisib | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT04358458 | Phase Ib/II | GEN3009 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Terminated | USA | NLD | ESP | DNK | BEL | 0 |
NCT04384484 | Phase III | Loncastuximab tesirine-lpyl + Rituximab Gemcitabine + Oxaliplatin + Rituximab | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | CZE | CHE | CAN | BRA | BEL | ARG | 5 |
NCT04442022 | Phase II | Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | POL | ITA | ISR | ESP | AUT | 1 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT04502706 | Phase I | FSI-189 FSI-189 + Rituximab | Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | CZE | BEL | AUT | 2 |
NCT04531046 | Phase II | axicabtagene ciloleucel | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | Active, not recruiting | FRA | BEL | 0 |
NCT04535102 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | POLA+BR for Relapsed or Refractory DLBCL | Withdrawn | 0 | |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04546620 | Phase II | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A) | Recruiting | GBR | 0 |
NCT04548648 | Phase II | Acalabrutinib Isavuconazole | LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | Recruiting | USA | 0 |
NCT04555811 | Phase I | FT596 + Rituximab | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | Completed | USA | 0 |
NCT04572763 | Phase Ib/II | Copanlisib + Venetoclax | Copanlisib Plus Venetoclax in R/R DLBCL | Active, not recruiting | USA | 0 |
NCT04578600 | Phase I | Azacitidine + Lenalidomide + Obinutuzumab | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 3 |
NCT04594798 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | Recruiting | USA | 0 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Completed | USA | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Active, not recruiting | USA | 0 |
NCT04657224 | Phase I | JNJ-64264681 + JNJ-67856633 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | POL | NLD | ISR | FRA | ESP | BEL | AUS | 4 |
NCT04665765 | Phase II | Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04739813 | Phase I | Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | Recruiting | USA | 0 |
NCT04746131 | Phase I | IMM0306 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | Suspended | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04799275 | Phase II | Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04824092 | Phase III | Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | AUS | ARG | 10 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04833114 | Phase III | Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) | Recruiting | GBR | ESP | DEU | AUT | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04844866 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) | Active, not recruiting | SWE | POL | NLD | LTU | ITA | HUN | FRA | ESP | DEU | CZE | BEL | AUT | 0 |
NCT04855253 | Phase Ib/II | E7777 | Study of E7777 Prior to Kymriah for R/R DLBCL | Recruiting | USA | 0 |
NCT04882163 | Phase Ib/II | Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | Withdrawn | USA | GBR | FRA | ESP | BEL | AUT | 2 |
NCT04884035 | Phase I | CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine Sulfate | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphom | Recruiting | USA | POL | GRC | ESP | AUS | 2 |
NCT04889716 | Phase II | Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb | CAR-T Followed by Bispecific Antibodies | Recruiting | USA | 0 |
NCT04914741 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisolone + Rituximab | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION) | Active, not recruiting | AUS | 0 |
NCT04933617 | Phase I | Copanlisib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | Terminated | USA | 0 |
NCT04974216 | Phase II | Lenalidomide + Rituximab + Tafasitamab-cxix | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | Active, not recruiting | FRA | BEL | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04980222 | Phase II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | POL | NLD | FRA | ESP | DNK | 0 |
NCT04989803 | Phase I | Cyclophosphamide + Fludarabine + KITE-363 | Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Recruiting | USA | NLD | GBR | DEU | 0 |
NCT05016947 | Phase I | Dexamethasone + Inotuzumab ozogamicin + Venetoclax | Venetoclax Plus Inotuzumab for B-ALL | Recruiting | USA | 0 |
NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT05024045 | Phase I | LOXO-338 + Pirtobrutinib LOXO-338 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | Active, not recruiting | USA | POL | ITA | FRA | 0 |
NCT05025800 | Phase Ib/II | Evorpacept + Lenalidomide + Rituximab | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05075603 | Phase I | Tisagenlecleucel | A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah) in Relapsed/Refractory Large B-cell Lymphoma Subjects | Recruiting | USA | 0 |
NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05098613 | Phase I | CD19/CD22 CAR T cells | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | Recruiting | USA | 0 |
NCT05171647 | Phase III | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) | Active, not recruiting | USA | TUR | NZL | ISR | CAN | BRA | ARG | 6 |
NCT05202782 | Phase II | Zanubrutinib | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT05206357 | Phase I | Epcoritamab-bysp | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | Recruiting | USA | TUR | ITA | ISR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT05207670 | Phase II | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | Active, not recruiting | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Active, not recruiting | USA | 0 |
NCT05253495 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) | Recruiting | USA | 0 |
NCT05256641 | Phase Ib/II | Acalabrutinib | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05260957 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Recruiting | USA | 0 |
NCT05270057 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) | Recruiting | USA | 0 |
NCT05272384 | Phase I | Decitabine and Cedazuridine + Nivolumab | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05283720 | Phase II | Epcoritamab-bysp + Lenalidomide Epcoritamab-bysp + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Recruiting | USA | NLD | ISR | HUN | FRA | ESP | DNK | DEU | CZE | 3 |
NCT05296525 | Phase Ib/II | GDA-201 | Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | Terminated | USA | 0 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05359211 | Phase I | NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |
NCT05364424 | Phase I | Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Obinutuzumab + Rituximab + Tocilizumab Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Obinutuzumab + Rituximab | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05412290 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05421663 | Phase I | C-CAR039 | A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | NLD | GBR | ESP | DNK | CAN | AUS | 1 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05451810 | Phase II | Epcoritamab-bysp | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | Recruiting | USA | 1 |
NCT05455697 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate | Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05459571 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) | Active, not recruiting | USA | 0 |
NCT05463263 | Phase Ib/II | STP938 | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Recruiting | USA | GBR | FRA | 0 |
NCT05464329 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05464719 | Phase II | Loncastuximab tesirine-lpyl | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | Recruiting | USA | 0 |
NCT05487651 | Phase I | KUR-502 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2) | Recruiting | USA | 0 |
NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05544019 | Phase I | SGR-1505 | Study of SGR-1505 in Mature B-Cell Neoplasms | Recruiting | USA | 1 |
NCT05583149 | Phase II | Acalabrutinib + Lisocabtagene maraleucel | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | Recruiting | USA | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05605899 | Phase III | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | A Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 2 |
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |
NCT05643742 | Phase Ib/II | CTX112 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | AUS | 0 |
NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05757700 | Phase I | 19(T2)28z1xx TRAC CAR-T cells | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT05794958 | Phase I | axicabtagene ciloleucel | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | Recruiting | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05798156 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive Large B-cell Lymphoma Ineligible for R-CHOP (R-Pola-Glo) | Recruiting | DEU | AUT | 0 |
NCT05801913 | Phase I | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05820841 | Phase III | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) | Recruiting | DEU | 0 |
NCT05821088 | Phase II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05824585 | Phase I | DZD8586 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |
NCT05826535 | Phase Ib/II | IMPT-314 | Study of IMPT-314 in R/R Aggressive B-cell | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |
NCT05890352 | Phase II | Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + Tazemetostat Lenalidomide + Tafasitamab-cxix + Zanubrutinib | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Recruiting | USA | 0 |
NCT05907759 | Phase II | Daratumumab | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma | Recruiting | USA | 0 |
NCT05908409 | Phase Ib/II | IDP-121 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | ESP | 0 |
NCT05950334 | Phase I | Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Recruiting | USA | 0 |
NCT06015880 | Phase I | Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT06047080 | Phase III | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 5 |
NCT06071871 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) | Recruiting | GBR | 0 |
NCT06101381 | Phase Ib/II | huCART19 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) | Not yet recruiting | BRA | 0 |
NCT06139406 | Phase I | JNJ-80948543 + JNJ-87801493 JNJ-75348780 + JNJ-87801493 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | Recruiting | ISR | ESP | DNK | AUS | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Not yet recruiting | CAN | 0 |
NCT06213311 | Phase II | Obinutuzumab axicabtagene ciloleucel + Glofitamab-gxbm | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT06218602 | Phase II | Fecal microbiota axicabtagene ciloleucel | Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. | Recruiting | USA | 0 |
NCT06238648 | Phase II | Epcoritamab-bysp | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Recruiting | USA | 0 |
NCT06242834 | Phase II | Pembrolizumab + Tazemetostat | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |
NCT06249191 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT06256484 | Phase I | ATA3219 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06271057 | Phase II | CC-99282 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | Recruiting | FRA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06287398 | Phase II | Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Recruiting | AUS | 0 |
NCT06290622 | Phase I | INCAGN02385 + INCAGN02390 + Retifanlimab | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Withdrawn | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06356129 | Phase III | CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NZL | NOR | NLD | ITA | HUN | HRV | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 14 |
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06414148 | Phase II | Epcoritamab-bysp + Lenalidomide + Rituximab Epcoritamab-bysp | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART) | Recruiting | AUS | 0 |
NCT06458439 | Phase II | Epcoritamab-bysp | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Recruiting | USA | 0 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06500273 | Phase II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | 0 |
NCT06534437 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + SEL24-B489 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01) | Not yet recruiting | POL | 0 |
NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT06594939 | Phase II | Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | Not yet recruiting | USA | 0 |